Compass Pathways Plc (CMPS NASDAQ) stock market data APIs
$2.8268
-0.05(-1.8%)
as of June 30, 2025
Try our APIs with
free plan!
Compass Pathways Plc Financial Data Overview
Price chart is built with
Anychart
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Prev. Close
2.8268
Open
2.7816
High
2.916
Low
2.6759
52 wk Range
2.25-8.5367
Market Cap
259 M
Shares Outstanding
93 562 K
EPS
-0.4185
Beta
2.254
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Compass Pathways Plc data using free add-ons & libraries
Get Compass Pathways Plc Fundamental Data
Compass Pathways Plc Fundamental data includes:
- Net Revenue:
- EBITDA: -162 595 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.49
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Compass Pathways Plc News
New
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Weedmaps co-founders withdrew buyout offer, but left door open for future deal High Tide launched “Buy Local” cannabis campaign across Canada to celebrate Canada Da...
This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?
A concept image of a woman placing a psychedelic pill in her open mouth by BLACKDAY via Shutterstock_com Psychedelic stocks are gaining attention as new ways to treat mental illnesses like depression...
Compass Pathways stock holds Buy rating on positive depression trial
Investing.com - H.C. Wainwright maintained its Buy rating and $45.00 price target on Compass Pathways (NASDAQ:CMPS) following breakthrough clinical trial results for its psilocybin therapy. The global...
Compass Pathways price target lowered to $7 by BTIG on drug concerns
Investing.com - BTIG lowered its price target on Compass Pathways (NASDAQ:CMPS) to $7.00 from $12.00 on Tuesday while maintaining a Buy rating, citing concerns about the company’s COMP360 drug devel...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
